Y-MAbs Therapeutics Says Preclinical GD2-SADA Data Will Be Presented At Society Of Nuclear Medicine & Molecular Imaging 2024 Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Y-MAbs Therapeutics announced that preclinical data on their GD2-SADA technology will be presented at the Society of Nuclear Medicine & Molecular Imaging 2024 Annual Meeting.
June 07, 2024 | 11:09 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Y-MAbs Therapeutics will present preclinical data on their GD2-SADA technology at a major medical conference, potentially increasing visibility and investor interest.
Presenting at a major medical conference can increase visibility and credibility for Y-MAbs Therapeutics, potentially attracting investor interest and positively impacting the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100